Candel Therapeutics于ASTRO 2026披露新数据:局部前列腺癌患者接受Aglatimagene Besadenovec治疗后两年余仍见持续性免疫重塑
Candel Therapeutics于ASTRO 2026披露新数据:局部前列腺癌患者接受Aglatimagene Besadenovec治疗后两年余仍见持续性免疫重塑
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.